文献速递类风湿关节炎

多生物标志物疾病活动度与临床疾病活动度评分在持续性活动性类风湿关节炎患者中的差异

Discrepancy Between Multibiomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2022-05-24

本研究在多中心随机安慰剂对照的 repository corticotropin injection(RCI)试验中,比较 MBDA 评分与 DAS28-ESR、CDAI 评估持续性活动性 RA 疾病活动度的效用。结果显示 RCI 治疗后 DAS28-ESR 和 CDAI 有临床意义改善,但 MBDA 改善低于最小重要差异阈值,MBDA 与 DAS28-ESR、CDAI 相关性普遍较低。结论提示 MBDA 总分对 RCI 治疗后 RA 疾病活动度评估反应性不足,不应作为临床实践中的首选疾病活动度指标。

要点

  • RCI 治疗后 DAS28-ESR 和 CDAI 显示临床意义改善,但 MBDA 改善未达最小重要差异阈值。
  • MBDA 总分及各组分与 DAS28-ESR、CDAI 的相关性普遍较低(r ≤ 0.3),偶有中等相关(r > 0.3 但 r < 0.5)。
  • MBDA 总分对 RCI 治疗后 RA 疾病活动度评估反应性不足,不应作为临床首选疾病活动度指标。

核心结论

  • MBDA 总分对 RCI 治疗后 RA 疾病活动度评估反应性不足,不应作为临床实践中的首选疾病活动度指标。

研究设计与样本

  • 多中心、随机、安慰剂对照试验,纳入持续性活动性 RA 患者,先接受 80 单位 RCI 每周两次共 12 周开放标签期,第 12 周达到低疾病活动度者随机接受 80 单位 RCI 或安慰剂每周两次共 12 周双盲期。

主要发现

  • RCI 治疗后 DAS28-ESR 和 CDAI 较基线的变化提示疾病活动度有临床意义改善,但 MBDA 评分较基线的改善低于最小重要差异阈值。
  • MBDA 总分及各组分与 DAS28-ESR、CDAI 的相关性普遍较低(r ≤ 0.3),偶有中等相关(r > 0.3 但 r < 0.5)。

关键数值与推荐

  • MBDA 评分改善低于最小重要差异阈值;MBDA 与 DAS28-ESR、CDAI 相关性普遍为 r ≤ 0.3,偶有 r > 0.3 但 r < 0.5。

临床怎么用

  • 在临床实践中评估 RA 疾病活动度时,不应将 MBDA 作为首选疾病活动度指标。

局限性

  • 研究结果来自临床试验,可能不完全代表临床实践人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Responsive assessment of disease activity in patients who have rheumatoid arthritis (RA) is necessary to evaluate therapeutic efficacy and guide treatment. We compared the utility of the multibiomarker disease activity (MBDA) score in the assessment of RA disease activity with that of the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR) score and the Clinical Disease Activity Index (CDAI) in a multicenter, randomized, placebo-controlled trial of repository corticotropin injection (RCI) in patients with persistently active RA. METHODS: Patients received 80 units of RCI twice weekly during a 12-week open-label period; those who experienced low disease activity at week 12 were randomly assigned to receive either 80 units of RCI or placebo twice weekly during a 12-week double-blind period. Changes in disease activity (measured by DAS28-ESR, CDAI, and MBDA scores) and correlations between MBDA scores and both DAS28-ESR and CDAI scores were assessed. RESULTS: Changes from baseline in DAS28-ESR and CDAI scores suggested that RCI therapy led to clinically meaningful improvements in disease activity, but improvements from baseline in MBDA scores were below the minimally important difference threshold. For the DAS28-ESR and CDAI, correlations with total MBDA and individual component scores were generally low (r ≤ 0.3) and occasionally moderate (r > 0.3 but r < 0.5). CONCLUSION: The results of the present study suggest overall MBDA scores are not sufficiently responsive for assessing RA disease activity after RCI therapy. These findings are consistent with those seen with other RA drugs and, although they are from a clinical trial, suggest the MBDA should not be a preferred disease activity measure in clinical practice.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Fleischmann R, Liu J, Zhu J, et al. Discrepancy Between Multibiomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2022. PMID: 33644992. doi:10.1002/acr.24583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。